

# The Medical Letter<sup>®</sup>

## On Drugs and Therapeutics

---

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

---

**IN THIS ISSUE** (starts on next page)

**In Brief: Biennial IV Zoledronic Acid (*Reclast*) for Prevention of Osteoporosis** ..... p 49

## Important Copyright Message

The Medical Letter<sup>®</sup> publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769**

---

**FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter publications are protected by US and international copyright laws.  
Forwarding, copying or any other distribution of this material is strictly prohibited.  
For further information call: 800-211-2769

# The Medical Letter®

## On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 51 (Issue 1315)  
June 29, 2009

[www.medicalletter.org](http://www.medicalletter.org)

### IN BRIEF

#### **Biennial IV Zoledronic Acid (*Reclast*) for Prevention of Osteoporosis**

The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (*Reclast* – Novartis) once a year for treatment of postmenopausal osteoporosis ([Med Lett Drugs Ther 2007; 49:89](#)), has now approved the same dose for use once every 2 years to prevent osteoporosis in postmenopausal women with osteopenia.

**Clinical Studies** – In an unpublished study summarized in the package insert, 224 women with osteopenia <5 years after menopause were given an IV infusion of zoledronic acid 5 mg or placebo; 2 years later, total hip bone mineral density (BMD) had increased by 2.6% with the drug and decreased by 2.1% with placebo. Among 357 osteopenic women ≥5 years after menopause, hip BMD 2 years after one IV dose of zoledronic acid increased by 2.1% and decreased by 1.0% with placebo. Both of these differences from placebo were statistically significant. Similarly significant increases occurred in vertebral BMD. No data are available on the incidence of hip or vertebral fractures in these women, but zoledronic acid once a year for treatment of osteoporosis has been shown to decrease the incidence of such fractures.

**Adverse Effects** — An acute-phase reaction including fever, flu-like symptoms, headache, arthralgia and myalgia can occur with IV administration of zoledronic acid; symptoms usually subside within a few days. Renal damage can occur after a single dose, especially with concomitant use of other nephrotoxic drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs). Jaw osteonecrosis has occurred rarely. Whether long-term use of bisphosphonates, which interfere with bone remodeling, could increase

the incidence of long-bone fractures remains to be established. None of these events, except for acute-phase reactions, occurred during the clinical trial, according to the manufacturer.

**Cost** – The cost of one 5-mg injection of *Reclast* is about \$1200 for the drug alone.

The Medical Letter®  
On Drugs and Therapeutics

**EDITOR IN CHIEF:** Mark Abramowicz, M.D.

**EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

**EDITOR:** Jean-Marie Pflomm, Pharm.D.

**ASSISTANT EDITORS, DRUG INFORMATION:** Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.

**ADVISORY BOARD:**

Jules Hirsch, M.D., Rockefeller University

Gerald L. Mandell, M.D., University of Virginia School of Medicine

Dan M. Roden, M.D., Vanderbilt University School of Medicine

**CONTRIBUTING EDITORS:**

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons

Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D. Albert Einstein College of Medicine

David N. Juurlink, BPhm, M.D., PhD, Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Hans Meinertz, M.D., University Hospital, Copenhagen

Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba

Jordan W. Smoller, M.D., Sc.D., Harvard Medical School

Neal H. Steigbigel, M.D., New York University School of Medicine

**EDITORIAL FELLOWS:** Lauren K. Schwartz, M.D., Mount Sinai School of Medicine

Manouchkathé Cassagnol, Pharm.D., St. John's University

**SENIOR ASSOCIATE EDITORS:** Donna Goodstein, Amy Faucard

**ASSOCIATE EDITOR:** Cynthia Macapagal Covey

**MANAGING EDITOR:** Susie Wong

**ASSISTANT MANAGING EDITOR:** Liz Donohue

**PRODUCTION COORDINATOR:** Cheryl Brown

**EXECUTIVE DIRECTOR OF SALES:** Gene Carbona

**FULFILLMENT & SYSTEMS MANAGER:** Cristine Romatowski

**DIRECTOR OF MARKETING COMMUNICATIONS:** Joanne F. Valentino

**VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations.

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

**Subscription Services**

**Mailing Address:**

The Medical Letter, Inc.  
1000 Main Street  
New Rochelle, NY 10801-7537

**Customer Service:**

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
Web Site: www.medicalletter.org  
E-mail: custserv@medicalletter.org

**Permissions:**

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

**Subscriptions (US):**

1 year - \$98; 2 years - \$167;  
3 years - \$235. \$49.00 per year for students, interns, residents and fellows in the US and Canada. CME: \$70 for 26 credits.

**E-mail site license inquiries to:**

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.